LICENSE AGREEMENT by and between Blueprint Medicines Corporation and Clementia Pharmaceuticals, Inc. Dated as of October 15, 2019License Agreement • November 5th, 2019 • Blueprint Medicines Corp • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is effective as of October 15, 2019 (the “Effective Date”), by and between Blueprint Medicines Corporation, a Delaware corporation with offices at 45 Sidney Street, Cambridge, MA, 02139 U.S.A. (“Blueprint”), and Clementia Pharmaceuticals, Inc., 1000 de la Gauchetière Street West, Suite 1200, Montreal, QC, H3B 4W5, Canada (“Clementia”). Blueprint and Clementia are each sometimes referred to herein as a “Party” or collectively as the “Parties.” Capitalized terms used but not defined in this paragraph and the Recitals below will have the meanings ascribed to such terms in Article 1 or elsewhere in this Agreement.
SIXTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTSixth Amendment • November 5th, 2019 • Blueprint Medicines Corp • Pharmaceutical preparations • New York
This Sixth Amendment (this “Sixth Amendment”), effective November 1, 2019 (“Sixth Amendment Effective Date”), is by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (together referred to as “Roche”), and Blueprint Medicines Corporation, with a principal place of business at 45 Sidney Street, Cambridge, Massachusetts 02139 U.S.A. (“BPM”). Capitalized terms used and not otherwise defined in this Sixth Amendment shall have the meanings set forth in the Agreement (as defined below).
